Oculis Holding Stock Price, News & Analysis

Oculis Holding AG (Nasdaq: OCS) has announced its 2025 Annual General Meeting, scheduled for June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland. The meeting will take place at 3:00 p.m. CEST / 9:00 a.m. EDT and will be held both in-person and via broadcast.

Prior to the AGM, the company will host a virtual information session on May 19, 2025 from 4:00 to 5:00 p.m. CEST, where management will present the meeting proposals and address shareholder questions. Meeting materials and webcast replay will be available on the Oculis website.

Oculis Holding AG (Nasdaq: OCS) reported Q1 2025 financial results and significant progress across its pipeline. The company ended Q1 with $206.3 million in cash, providing runway into early 2028, bolstered by a $100 million financing in February 2025. Key developments include:

- OCS-01: Completed enrollment of over 800 patients in Phase 3 DIAMOND trials for diabetic macular edema (DME), with topline results expected Q2 2026

- Licaminlimab (OCS-02): Aligned with FDA on genotype-based development plan for dry eye disease, with first registrational trial planned for 2H 2025

- Privosegtor (OCS-05): Reported positive Phase 2 ACUITY trial results in acute optic neuritis, showing neuroprotective benefits

Q1 2025 net loss was CHF 33.2 million ($36.9 million), or CHF 0.69 per share, compared to CHF 16.1 million in Q1 2024. R&D expenses increased to CHF 14.8 million, primarily due to clinical trial costs.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in four major investor conferences in May 2025:

• Bio€quity Europe in Bruges (May 12-14)
• Bank of America Healthcare Conference in Las Vegas (May 13-15)
• H.C. Wainwright BioConnect at Nasdaq in New York (May 20)
• Stifel Virtual Ophthalmology Forum (May 27)

CEO Riad Sherif and CFO Sylvia Cheung will present company updates and participate in fireside chats. One-on-one meetings will be available for interested investors through sponsoring institutions. Webcast links will be posted on the company's website.

Oculis Holding (Nasdaq: OCS) announces upcoming presentations of its late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress.

Key highlights include:

• OCS-01 eye drops for DME (Diabetic Macular Edema) - First non-invasive treatment showing positive Phase 3 DIAMOND program results
• Licaminlimab (OCS-02) for dry eye disease (DED) - Phase 2b RELIEF trial data featuring a genetic biomarker-based personalized approach

Presentations will feature insights from the DME AWARE Delphi Study on unmet needs in patient management and detailed efficacy data from the DIAMOND Stage 1 trial. Distinguished speakers include Dr. Anat Loewenstein, Dr. Carl Danzig, Dr. Anat Galor, and Dr. David Almeida, leading experts in ophthalmology.

Oculis Holding, a global biopharmaceutical company, announces upcoming presentations of its late-stage pipeline at major ophthalmology conferences including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress.

Key highlights include the DME AWARE Delphi Study interim results and insights from the Phase 3 DIAMOND program for OCS-01, potentially the first non-invasive treatment for DME. The company will also present data from the Phase 2b RELIEF trial of Licaminlimab (OCS-02) for dry eye disease (DED), featuring a genetic biomarker-based approach.

Notable presentations will be delivered by distinguished experts including Dr. Sharon Klier, Dr. Anat Loewenstein, Dr. Carl Danzig, Dr. Anat Galor, Dr. Riad Sherif, and Dr. David Almeida across multiple sessions focusing on retinal diseases and innovative treatments.

Oculis Holding AG (Nasdaq: OCS) has announced an update to its share capital structure. The company has issued 589,974 new registered ordinary shares with a nominal value of CHF 0.01 each. This issuance consists of:

• 310,941 shares issued for equity awards under the Company's Stock Option and Incentive Plan
• 279,033 shares issued through EBAC warrant exercises

Following these issuances, which occurred between January 1, 2024, and December 31, 2024, Oculis's total registered shares have increased to 54,533,674. The change has been officially registered with the Zug Commercial Register.

Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced the 2025 Ramin Tadayoni Award, continuing their collaboration to honor the legacy of Professor Tadayoni, who passed away on April 19, 2024. The award, worth €30,000 for research support plus €5,000 for the candidate, aims to support exceptional postgraduate scholars in retina research.

Applications will be accepted until May 12, 2025, with the winner to be announced at the EURETINA Congress in Paris (September 4-7, 2025). Dr. Andrea Govetto was named the inaugural recipient in 2024 for his work on developing a computational model of fluid flow and retinal tissue deformation in macular edema.

Professor Tadayoni served as Oculis' Chief Scientific Officer and was a distinguished figure in ophthalmology, having authored over 320 medical articles and received numerous prestigious awards including the Jules Gonin Award.

Oculis (OCS) is hosting an R&D Event to showcase progress on its three pipeline assets. Key highlights include:

• Updates on DIAMOND and EMERALD Phase 3 trials for DME with >800 enrolled patients and topline data expected in Q2 2026
• Development plans for Licaminlimab (OCS-02) in dry eye disease with Phase 2/3 study starting in H2 2025
• New data from ACUITY Phase 2 trial for Privosegtor (OCS-05) in acute optic neuritis

The company also announced expansion of Privosegtor development into non-arteritic anterior ischemic optic neuropathy (NAION) and multiple sclerosis relapses. A follow-up investor meeting is scheduled in Iceland on April 29, 2025.